ImmunoGen, Inc.  

(Public, NASDAQ:IMGN)   Watch this stock  
Find more results for Dean Morris
13.79
-0.11 (-0.79%)
After Hours: 14.15 +0.36 (2.61%)
Apr 24, 7:02PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 13.25 - 14.17
52 week 11.78 - 20.25
Open 13.96
Vol / Avg. 764,385.00/990,745.00
Mkt cap 1.18B
P/E     -
Div/yield     -
EPS -0.36
Shares 85.67M
Beta 1.77
Inst. own 88%
Apr 25, 2014
Q3 2014 ImmunoGen, Inc. Earnings Conference Call - 8:00AM EDT - Add to calendar
Apr 25, 2014
Q3 2014 ImmunoGen, Inc. Earnings Release - 6:30AM EDT - Add to calendar
Mar 11, 2014
ImmunoGen, Inc. at ROTH Conference
Mar 4, 2014
ImmunoGen, Inc. at Cowen Health Care Conference
Feb 25, 2014
ImmunoGen, Inc. at RBC Capital Markets Healthcare Conference
Feb 13, 2014
ImmunoGen, Inc. at Leerink Swann Global Healthcare Conference
Jan 31, 2014
Q2 2014 ImmunoGen, Inc. Earnings Conference Call - Webcast
Jan 31, 2014
Q2 2014 ImmunoGen, Inc. Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin 12.68% -204.90%
Operating margin 12.48% -205.46%
EBITD margin - -192.40%
Return on average assets 7.60% -36.97%
Return on average equity 12.26% -70.78%
Employees 245 -
CDP Score - -

Address

830 WINTER ST
WALTHAM, MA 02451
United States - Map
+1-781-8950600 (Phone)
+1-781-8950611 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

ImmunoGen, Inc. (ImmunoGen) develops targeted, antibody-based therapeutics for the treatment of cancer. ImmunoGen designs linkers that enable antibody-based therapeutics for the treatment of cancer agents to remain stably attached to the antibodies while in the blood stream and be released in their fully active form after delivery to a cancer cell. An anticancer compound made using the Company�s Targeted Antibody Payload (TAP), technology consists of a monoclonal antibody. The Company's TAP technology is designed to enable the creation of well-tolerated anticancer products. As of June 30, 2012, ImmunoGen had three wholly owned clinical-stage product candidates included IMGN901, IMGN853, and IMGN529, and other TAP compounds in earlier stages of development.

Officers and directors

Stephen C. McCluski Independent Chairman of the Board
Bio & Compensation  - Reuters
Daniel M. Junius President, Chief Executive Officer, Director
Age: 61
Bio & Compensation  - Reuters
David B. Johnston Chief Financial Officer, Executive Vice President, Principal Financial Officer, Principal Accounting Officer
Age: 58
Bio & Compensation  - Reuters
Ellie Harrison Chief Human Resource Officer, Vice President
Bio & Compensation  - Reuters
John M. Lambert Ph.D. Executive Vice President - Research and Development, Chief Scientific Officer
Age: 62
Bio & Compensation  - Reuters
Charles Q. Morris Executive Vice President, Chief Development Officer
Age: 48
Bio & Compensation  - Reuters
Craig Barrows Vice President, General Counsel, Secretary
Bio & Compensation  - Reuters
Eric Guempel Vice President - Product Strategy and Program Management
Bio & Compensation  - Reuters
James J. O'Leary M.D. Vice President, Chief Medical Officer
Age: 49
Bio & Compensation  - Reuters
Theresa G. Wingrove Ph.D. Vice President - Regulatory Affairs
Age: 55
Bio & Compensation  - Reuters